Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses than that of the Partially Effective gB/MF59 Vaccine

Competing Interest Statement

S.R.P. is a consultant to Moderna, Merck, Pfizer, GSK, Dynavax, and Hoopika CMV vaccine programs and leads sponsored programs with Moderna and Merck. S.R.P. also serves on the board of the National CMV Foundation and as an educator on CMV for Medscape. E.B.W has received funding support from Pfizer, Moderna, Sequiris, Najit Technologies Inc, and Clinetic for the conduct of clinical trials and clinical research. E.B.W has served as an advisor to Vaxcyte and consultant to ILiAD biotechnologies. J.H., M.K., K.W., A.C. has Moderna company stocks. The other authors have no financial conflicts of interest.

Clinical Trial

NCT03382405 and NCT00133497

Funding Statement

This work was supported by Moderna Therapeutics SRA Project# OA22BEA4 and NIH R21 project # 5R21 AI136556 to S.R.P.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional review board (IRB) approval was obtained for the gB/MF59 cohort from the Cincinnati Childrens Hospital Medical Center, and samples were provided by the NIAID Vaccine Treatment and Evaluation Unit (grant #5R21 AI136556). For the mRNA-1647 study conducted by Moderna, the study protocol, amendments, and informed consent form were reviewed and approved by the Advarra IRB. Written informed consent was obtained from all participants prior to study recruitment and procedures. The study protocol adhered to all applicable national, state, and local laws or regulations, the principles of the International Council for Harmonisation harmonized tripartite guideline E6(R2): Good Clinical Practice and of the Declaration of Helsinki. All mRNA-1647 samples transferred to Duke and WCM from Moderna were de-identified, and the analysis of de-identified samples was exempt from human subjects research designation by the IRBs of Duke and WCM.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes